About 1 in 8 Americans takes a GLP-1 drug, according to a comprehensive 2025 poll by KFF, a health policy organization
These medications, including semaglutide and liraglutide, reduce appetite and slow gastric emptying, leading to decreased caloric intake and subsequent weight reduction in patients with obesity or overweight conditions with metabolic complications
Approved locations and personnel: Dispensing would be allowed only at licensed premises, such as pharmacies with an on-duty pharmacist, healthcare facilities, or other sites licensed under the Drug Act
The telehealth site will welcome its own small-dose, compounded version of semaglutide, which mimics the function of a GLP-1
Since each pharmacy makes its own, there is no stringent regulatory oversight and quality control measures like those for FDA-approved medications